Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

  • End date
    Jun 15, 2026
  • participants needed
  • sponsor
    Vanderbilt University Medical Center
Updated on 7 August 2021


The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT).

The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer ( cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.


The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT) is a randomized study to investigate blood sparing using autologous normovolemic hemodilution (ANH) or cell salvage at the time of nephrectomy for locally advanced kidney cancer after assessing inclusion criteria patients will be randomized to undergo standard blood management including the possibility of allogenic transfusion vs autologous blood transfusion. There are multiple ways patients can receive allogenic or autologous blood, including veno-venous bypass or cardiopulmonary bypass (typically reserved for patients with a thrombus above the level of the hepatic veins or entering the heart).

Condition urinary tract neoplasm, Malignant neoplasm of kidney, Nephropathy, Kidney Cancer, Renal Cancer, cancer, renal
Treatment Blood Sparing Protocol, Standard Blood Replacement
Clinical Study IdentifierNCT04922307
SponsorVanderbilt University Medical Center
Last Modified on7 August 2021


Yes No Not Sure

Inclusion Criteria

Renal masses cT2 (by any conventional imaging)
N1 or M1 disease is allowed if they are deemed surgical candidates (including cytoreductive nephrectomy)
Male and female patients
and older
Ejection fraction (EF) 45% by echocardiogram (ECHO)
Adequate organ function as defined by
Hemoglobin 9 g/dL. Pre-operative allogenic blood transfusion is allowed
Platelets 100.000/l
Albumin 2.5 g/dL
Aspartate Aminotransferase (AST) and alanine transaminase (ALT) 75U/L or total bilirubin 2.0 mg/dL
WBC within institutional normal limits
PT within institutional normal limits
INR < 1.5 and PTT normal
Consent and compliance with all aspects of the study protocol

Exclusion Criteria

Male and female younger than 18 years old
Non-surgical candidate
Unstable angina
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note